Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluate the efficacy and safety of upadacitinib as induction therapy in subjects with moderately to severely active Crohn's disease (CD) compared to placebo.
CTR20181735Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc.. Started Oct 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20181735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181735.